Quality of life and depression in patients with mastocytosis
Teplyuk N.P., Pyatilova P.M.
Sechenov University, Moscow
Mastocytosis is a rare disease characterized by the accumulation of mast cells (MCs) in various organs, with indolent or aggressive flow.
Aim: To assess the quality of life and mental state of patients with different subtypes of mastocytosis.
Patients and Methods: Questioning and assessing the neurological symptoms of 30 mastocytosis patients aged from 20 to 66 years was performed. Patients were divided into the following groups: cutaneous mastocytosis (CM) (n=2), indolent systemic mastocytosis (ISM) (n=4), smoldering systemic mastocytosis (SSM) (n=3), aggressive systemic mastocytosis (ASM) (n=3), mastocytosis in the skin (n=18). The quality of life was assessed using a validated questionnaire to determine the Dermatology Life Quality Index (DLQI), and the Beck Depression Inventory (BDI) was used to estimate the psychoemotional status.
Results: in all patients with systemic mastocytosis, in contrast to cutaneous mastocytosis, a decrease in the quality of life was detected and correlated with the aggressiveness of the disease. Neurological symptoms, including headaches and cognitive disorders, were noted in 20 of 30 patients with mastocytosis (67%). In 12 of 30 patients (40%), signs of depression (BDI≥10) were diagnosed, and in 50% — moderate and severe. The mean BDI score for CM, ISM, SSM and ASM was 5±5, 12±5, 13±5, 32±4, respectively. Statistically significant differences were noted between the patients with benign forms (CM, ISM and SSM) and aggressive forms of mastocytosis (in this case ASM), in which 100% of patients suffered from severe depression (p<0.05).
Conclusion: The quality of life and mental status are mediated by the extent of internal organ damage caused by the underlying disease, and not by concomitant pathology and / or cosmetic defect. In patients with mastocytosis, there is a high risk of damage to the nervous system.
Key words: mastocytosis, the quality of life, depression, neurological symptoms.
For citation: Teplyuk N.P., Pyatilova P.M. Quality of life and depression in patients with mastocytosis // RMJ. Medical Review. 2018. № 4. P. 40–42.
References
1. Valent P. et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal // Leuk Res. 2001. Vol. 25 (7). Р.603–625.
2. Jennings S. et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions // J Allergy Clin Immunol Pract. 2014. Vol. 2 (1). P.70–76.
3. Hermine O. et al. Case-control cohort study of patients’ perceptions of disability in mastocytosis // PLoS One. 2008. Vol. 3 (5). P.e2266.
4. Valent P. et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria // Eur J Clin Invest. 2007. Vol. 37 (6). P.435–453.
5. Van der Veer E. et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis // Allergy. 2012. Vol. 67 (3). P.431–438.
6. Bonadonna P. et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels // J Allergy Clin Immunol. 2009. Vol. 123 (3). P.680–686.
7. Alvarez-Twose I. et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms // J Allergy Clin Immunol. 2010. Vol. 125 (6). P.1269–1278 e2.
8. Brockow K., Metcalfe D. D. Mastocytosis // Chem Immunol Allergy 2010. Vol. 95. P.110–24.
9. Akin C., Valent P., Metcalfe D. D. Mast cell activation syndrome: Proposed diagnostic criteria // J Allergy Clin Immunol. 2010. Vol. 126 (6). P.1099–1104 e4.
10. Valent P. et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal // Int Arch Allergy Immunol. 2012. Vol. 157 (3). P.215–225.
11. Wimazal F. et al. Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience // Int Arch Allergy Immunol. 2012. Vol. 157 (4). P.399–405.
12. Castells M., Austen K. F. Mastocytosis: mediator-related signs and symptoms // Int Arch Allergy Immunol. 2002. Vol. 127 (2). P.147–152.
13. Moura D. S. et al. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy // PLoS One. 2011. Vol. 6 (10). P.e26375.
14. Georgin-Lavialle S. et al. Mast cells’ involvement in inflammation pathways linked to depression: evidence in mastocytosis // Mol Psychiatry. 2016. Vol. 21 (11). P.1511–1516.
15. Rogers M. P. et al. Mixed organic brain syndrome as a manifestation of systemic mastocytosis // Psychosom Med. 1986. Vol. 48 (6). P.437–447.
16. Silver R., Curley J. P. Mast cells on the mind: new insights and opportunities // Trends Neurosci. 2013. Vol. 36 (9). P.513–521.
17. Campbell D. J., Kernan J. A. Mast cells in the central nervous system. Nature, 1966. Vol. 210 (5037). P.756–757.
18. Cirulli F. et al. Increased number of mast cells in the central nervous system of adult male mice following chronic subordination stress // Brain Behav Immun. 1998. Vol. 12 (2). P.123–133.
19. Nautiyal K. M. et al. Brain mast cells link the immune system to anxiety-like behavior // Proc Natl Acad Sci USA. 2008. Vol. 105 (46). P.18053–18057.
20. Theoharides T. C. Mast cells and stress — a psychoneuroimmunological perspective // J Clin Psychopharmacol. 2002. Vol. 22 (2). P.103–108.
21. Frenzel L., Hermine О. Mast cells and inflammation // Joint Bone Spine. 2013. Vol. 80 (2). P.141–145.
22. Kawasaki H. et al. A tryptophan metabolite, kynurenine, promotes mast cell activation through aryl hydrocarbon receptor // Allergy 2014. Vol. 69 (4). P.445–452.
23. Zhou Y. et al. Aryl hydrocarbon receptor controls murine mast cell homeostasis // Blood. 2013. Vol. 121 (16). P.3195–3204.
24. Sibilano R. et al. The aryl hydrocarbon receptor modulates acute and late mast cell responses // J Immunol. 2012. Vol. 189 (1). P.120–127.
25. Kushnir-Sukhov N.M. et al. Clinical correlates of blood serotonin levels in patients with mastocytosis // Eur J Clin Invest. 2008. Vol. 38 (12). P.953–958.
26. Finlay A. Y., Khan G. K. Dermatology Life Quality Index (DLQI) — a simple practical measure for routine clinical use // Clin Exp Dermatol. 1994. Vol. 19 (3). P.210–216.
27. Beck A. T. et al. An inventory for measuring depression // Arch Gen Psychiatry. 1961. Vol. 4. P.561–571.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
